According to statistics, close to a half billion people are living with diabetes and that number is expected to increase by more than 50% in the next 25 years. Hologenix, the creator of Celliant infrared technology, embarked on an initial study to test the hypothesis that the technology can positively impact diabetic patients with vascular impairment. The objective of the study was to “evaluate changes in transcutaneous oxygen (TcPO2) and peripheral blood flow (laser Doppler, LD) in the hands and feet of diabetic patients with vascular impairment when Celliant gloves and stockings are worn.”
»We are excited to explore whether future studies of infrared, with its most common biological effects of increased localized blood flow and cellular oxygenation, could result in a breakthrough in diabetic patients with vascular impairment.«
Seth Casden, Co-Founder and CEO, Hologenix
Diabetic patients frequently suffer from a combination of peripheral neuropathy and peripheral artery disease, which particularly affects their feet. It has been estimated that the lifetime risk for the development of foot ulcers in diabetic patients can be as high as 25% percent and that the risk of amputation is 10-20 times higher than in non-diabetic subjects.
Celliant technology is a patented process for adding micron-sized thermo-responsive mineral particles to fibers, in this case polyethylene terephthalate (PET) fibers. The resulting Celliant yarns were woven into stockings and gloves containing either 82% Celliant polyester, 13% polyamide (PA) and 5% elastane (spandex) or for the placebo, 82% polyester with no Celliant, 13% PA and 5% elastane. Celliant products absorb body heat and re-emit the energy back to the body as infrared energy, which is non-invasive and increases temporary blood flow and cell oxygenation levels in the body.
While there was not a statistically significant result across all subjects, the study did show that some patients wearing Celliant stockings for 60 minutes had an increase of as much as 20% in tissue oxygenation and 30% in localized blood flow. According to the study’s conclusion, “the trends that were observed in favor of Celliant stockings suggest that a larger well-designed clinical trial should be undertaken and may provide evidence of clinical efficacy in treatment of the diabetic foot.”
The study also notes that there have been no documented or observed side effects of wearing these stockings, and they are relatively inexpensive compared to conventional pharmaceutical interventions.
Hologenix, LLC, Pacific Palisades, CA/USA, has embarked on a more comprehensive trial, “Study to Evaluate Celliant Diabetic Medical Socks to Increase Tissue Oxygenation and Incidence of Complete Wound Closure in Diabetic Foot Wounds” – NCT04709419, which focuses on the impact of Celliant technology to potentially improve tissue oxygenation and wound healing outcomes.
The full study was published in Journal of Textile Science & Engineering.
Celliant = registered trademark